Send to

Choose Destination
Arch Immunol Ther Exp (Warsz). 1993;41(3-4):199-203.

The effect of low dose oral human interferon alpha therapy on diarrhea in veal calves.

Author information

Amarillo Cell Culture Co. Inc., TX 79109.


Low doses of recombinant human interferon alfa 2a (rHuIFN-alpha 2a), were given orally in milk replacer formula to veal calves to determine the efficacy of rHuIFN-alpha 2a for protection against diarrhea, ear and/or respiratory tract infections common in vealing operations. Calves given rHuIFN-alpha 2a had fewer days and a lower incidence of diarrhea, compared to placebo-treated calves. Calves treated with rHuIFN-alpha 2a had significantly (P < 0.05) fewer ear infections and fewer total days of ear infection than did placebo-treated calves. The mortality rate was lower in the rHuIFN-alpha 2a treatment group (1.6%) than in the placebo treatment group (2.9%) and calves given rHuIFN-alpha 2a had a greater average weight gain (13.1 lbs. more per calf) than calves given placebo. These data demonstrate that orally administered rHuIFN-alpha 2a exhibited a protective effect against clinically significant signs of disease in veal calves, reduced the mortality rate in this population, and enhanced average weight gain.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center